Shorter and more potent inhibitor of PKC (IC50=100 nM) than Protein Kinase C (19-36), Pseudosubstrate Inhibitor (BML-P150).
Product Details
| Alternative Name: | PKC (19-31) |
| |
| Sequence: | H-Arg-Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-Lys-Asn-Val-OH |
| |
| Formula: | C67H48N26O16 |
| |
| MW: | 1544.0 |
| |
| CAS: | 121545-65-1 |
| |
| Formulation: | TFA salt. Lyophilized. |
| |
| Peptide Content: | ~80% |
| |
| Purity: | ≥97% (HPLC) |
| |
| Solubility: | Soluble in 5% acetic acid or in water. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Protein kinase C gamma-mediated phosphorylation of GluA1 in the postsynaptic density of spinal dorsal horn neurons accompanies neuropathic pain, and dephosphorylation by calcineurin is associated with prolonged analgesia: G. Miletic, et al.; Pain
156, 2514 (2015),
Application(s): Intrathecal injection,
Abstract;
Full Text
Protein kinase C contains a pseudosubstrate prototope in its regulatory domain: C. House & B.E. Kemp; Science
238, 1726 (1987),
Abstract;
